Patients with psoriasis have systemic and vascular inflammation and are at increased risk for myocardial infarction, stroke, and cardiovascular death. However, the underlying mechanism(s) mediating the link between psoriasis and vascular disease is incompletely defined. This study sought to determine whether chronic skin-specific inflammation has the capacity to promote vascular inflammation and thrombosis. Using the KC-Tie2 doxycycline-repressible (Dox-off) murine model of psoriasiform skin disease, spontaneous aortic root inflammation was observed in 33% of KC-Tie2 compared with 0% of control mice by 12 months of age (P=0.04) and was characterized by the accumulation of macrophages, T lymphocytes, and B lymphocytes, as well as by reduced collagen content and increased elastin breaks. Importantly, aortic inflammation was preceded by increases in serum tumor necrosis factor-α, IL-17A, vascular endothelial growth factor, IL-12, monocyte chemotactic protein-1, and S100A8/A9, as well as splenic and circulating CD11b(+)Ly-6C(hi) pro-inflammatory monocytes. Doxycycline treatment of old mice with severe skin disease eliminated skin inflammation and the presence of aortic root lesion in 1-year-old KC-Tie2 animals. Given the bidirectional link between inflammation and thrombosis, arterial thrombosis was assessed in KC-Tie2 and control mice; mean time to occlusive thrombus formation was shortened by 64% (P=0.002) in KC-Tie2 animals; and doxycycline treatment returned thrombosis clotting times to that of control mice (P=0.69). These findings demonstrate that sustained skin-specific inflammation promotes aortic root inflammation and thrombosis and suggest that aggressive treatment of skin inflammation may attenuate pro-inflammatory and pro-thrombotic pathways that produce cardiovascular disease in psoriasis patients.
Patients with psoriasis have systemic and vascular inflammation and are at increased risk for myocardial infarction, stroke, and cardiovascular death. However, the underlying mechanism(s) mediating the link between psoriasis and vascular disease is incompletely defined. This study sought to determine whether chronic skin-specific inflammation has the capacity to promote vascular inflammation and thrombosis. Using the KC-Tie2doxycycline-repressible (Dox-off) murine model of psoriasiform skin disease, spontaneous aortic root inflammation was observed in 33% of KC-Tie2 compared with 0% of control mice by 12 months of age (P=0.04) and was characterized by the accumulation of macrophages, T lymphocytes, and B lymphocytes, as well as by reduced collagen content and increased elastin breaks. Importantly, aortic inflammation was preceded by increases in serum tumor necrosis factor-α, IL-17A, vascular endothelial growth factor, IL-12, monocyte chemotactic protein-1, and S100A8/A9, as well as splenic and circulating CD11b(+)Ly-6C(hi) pro-inflammatory monocytes. Doxycycline treatment of old mice with severe skin disease eliminated skin inflammation and the presence of aortic root lesion in 1-year-old KC-Tie2 animals. Given the bidirectional link between inflammation and thrombosis, arterial thrombosis was assessed in KC-Tie2 and control mice; mean time to occlusive thrombus formation was shortened by 64% (P=0.002) in KC-Tie2 animals; and doxycycline treatment returned thrombosis clotting times to that of control mice (P=0.69). These findings demonstrate that sustained skin-specific inflammation promotes aortic root inflammation and thrombosis and suggest that aggressive treatment of skin inflammation may attenuate pro-inflammatory and pro-thrombotic pathways that produce cardiovascular disease in psoriasispatients.
Psoriasis is a chronic inflammatory skin disease affecting between 2.5–6 million patients in the United States. Clinical data have convincingly demonstrated that psoriasispatients have an increased risk for developing cardiovascular disease (CVD), including myocardial infarction and stroke (Ahlehoff ; Gelfand ; Gelfand ; Mehta ; Mehta ; Prodanovich ) and an increased risk of thromboembolic events (Ahlehoff ). Psoriasispatients have more established CVD risk factors, including higher levels of serum cholesterol and triglycerides coupled with low HDL (Pietrzak ; Toker ), elevated pro-inflammatory mediators, (i.e. IL-17, IL-23 (Kryczek ) and S100A8/A9 (Benoit )), and decreases in anti-inflammatory mediators such as IL-10 and adiponectin (Kaur ; Takahashi ) and these correlate with disease severity (Boehncke ). Psoriasis is accompanied by impaired endothelial function (Balci ) and increased subclinical atherosclerosis as measured by carotid intimal-medial thickness measurements (Balci ), arterial stiffness (Gisondi ), and coronary calcium scores (Ludwig ). More recent work suggests that psoriasis confers an additional 6.2% absolute risk of a 10-year rate of major adverse cardiac events compared with the general population (Mehta ). However, these epidemiological studies do not provide insight as to the etiology of this elevated risk and rely on adjusting for confounders such as hyperlipidemia, hypertension, and diabetes and thus cannot demonstrate causality.Common inflammatory cascades play critical roles in the initiation and maintenance of psoriasis and CVD (Alexandroff ; Libby, 2002; Lowes ; Spah, 2008), including activation of antigen presenting cells and macrophages, involvement of Th1, Th17 and regulatory T cells, and a critical role for IL-12p40 and TNF-α. Psoriasispatients have significant inflammation not only in the skin, but also subclinical inflammation in the liver, joints, tendons and vascular tree even after adjusting for traditional cardiovascular risk factors (Mehta ), suggesting that psoriasis itself predisposes to pro-inflammation pathways independent of traditional risk factors. Others have suggested a more direct hypothesis that psoriasis-initiated skin and systemic inflammation cause insulin resistance, which promotes endothelial cell dysfunction, subsequent atherosclerosis and ultimately myocardial infarction or stroke (Boehncke ).Despite the epidemiological association between psoriasis and CVD, the underlying mechanism(s) mediating the link between psoriasis and vascular disease is incompletely defined. Whether localized, chronic cutaneous inflammation directly promotes vascular inflammation and thrombosis is unknown. To address this question, we used the KC-Tie2murine model of psoriasiform skin inflammation, in which Tie2 transgene expression is confined to keratinocytes and which recapitulates many characteristics of human plaque psoriasis (Johnston ; Ostrowski ; Swindell ; Ward ; Wolfram ). We hypothesized that the presence of sustained skin-confined inflammation would predispose animals to vascular inflammation and thrombosis.
RESULTS
Lesion characterization
At 12 months of age on a standard chow diet, spontaneous development of robust aortic root inflammation was observed in 33% of KC-Tie2mice with psoriasiform skin disease compared to 0% of control mice (P=0.04) (Figure 1a–d). Lesion formation, quantified by measuring vessel wall area of the aortic root at the level of the aortic valve was higher in the KC-Tie2mice compared to control mice (325 ± 48 μm2 vs. 221 ± 12 μm2, n=18–19 per group; P=0.04) (Figure 1e). No lesions were detected in the descending thoracic or abdominal aorta. Aortic root lesions were also stained with oil-red O and Sudan IV for lipid deposition. There was no significant lipid staining in the inflamed aortic roots of KC-Tie2mice on a standard chow diet.
Figure 1
Aortic roots develop spontaneous vascular inflammation by 1 year of age in KC-Tie2 and not control animals. Aortic roots from control (a, c) and KC-Tie2 (b, d) animals stained with H&E. Quantitation of aortic root vessel wall area (e) demonstrates significant increases in area of KC-Tie2 mice (n=19) compared to control littermates (n=18). Immunohistological staining and quantitative analyses of positively stained CD45+ (f–h), Mac-3+ (i–k), CD3+ (l–n) and B220+ cells (o–q) (% positively stained area) within the aortic roots of representative control (f, l, i, o; n = 5) and KC-Tie2 mice with vascular inflammation (g, j, m, p; n=5) reveals significant increases in inflammatory cell infiltrates. * P <0.05 vs control animals. Scale bar = 100 μm.
Examination of the aortic root revealed significant accumulation of inflammatory cells (CD45-positive leukocytes; Figure 1f–h) in KC-Tie2mice (13.5 ± 2.9% CD45-poitive area) compared to control animals (2.5 ± 1.4%, P<0.001) and affected all layers of the vessel wall. Leukocyte subset analysis was performed by staining for macrophages (Figure 1i–k), T-cells (Figure 1l–n), and B-cells (Figure 1o–q). Macrophage accumulation was increased 2.8-fold in KC-Tie2mice (13.8 ± 1.7% Mac-3-positive area) compared to controls (4.9 ± 1.2%, P<0.0001). Both T-cell and B-cell accumulation in the aortic root were enhanced in KC-Tie2mice with a 3.9-fold increase in T-cells (12.2 ± 2.0% vs. 3.2 ± 0.7% CD3-positive area, P=0.0004) and a 2.2-fold increase in B-cells (18.4 ± 2.4% vs 8.3 ± 1.9% B220-positive area, P=0.0003).Examination of the extracellular matrix (ECM) using Trichrome staining revealed decreased collagen content in the lesions in KC-Tie2 animals compared to the dense collagen content observed in control mice (Figure 2a–d). Aortic elastin integrity was investigated by Verhoeff elastin staining and revealed abundant elastin breaks and fragmentation in the aortic root lesions of KC-Tie2mice (Figure 2e–h).
Figure 2
Anatomical characterization of aortic arch lesions. Aortic roots from control (a, c, e, g) and KC-Tie2 (b, d, f, h) animals stained with Trichrome (a–d) or Verhoeff–van Gieson elastin (e–h) reveals decreased expression of collagen in Trichrome stained aortic arch tissue from KC-Tie2 mice and increases in the numbers of elastin breaks in Verhoeff–van Gieson elastin stained aortic root tissues. Scale bar = 100 μm.
To verify that transgene expression was limited to the skin, we performed additional matings between the K5tTA driver mouse and nuclear LacZ reporter mouse lines and analyzed LacZ expression in the skin, spleen, brain, liver, kidney, lung, heart, and aorta of the of KC-LacZ mice (Supplemental Figure 1). Robust LacZ expression was observed in the skin with little to no expression in the other tissues including the aorta. In addition, we verified the absence of aberrant Tie2 expression in the aortic roots of KC-Tie2mice that developed vascular inflammation (Supplemental Figure 1). Taken together, these observations indicate that chronic, skin-specific inflammation in KC-Tie2mice promotes the de novo development of aortic root inflammation and alterations in the ECM.
Systemic inflammation
Biomarkers associated with CVD risk were examined in KC-Tie2mice. Serum levels of MCP-1 (1.7-fold; P=0.038), IL-12p70 (4.3-fold; P=0.048), TNF-α (2.1-fold; P=0.05), IL17a (4.4-fold; P=0.038) and VEGF (1.6-fold; P=0.02) were all elevated in KC-Tie2mice compared to age-matched littermate controls (Figure 3a). The expression of the pro-inflammatory mediator S100A8/A9 (myeloid related protein-8/14, MRP-8/14) was also increased in the skin and serum of KC-Tie2 compared to control mice (Figure 3b).
Figure 3
Aortic root vascular inflammation develops in the presence of elevated systemic inflammation and monocytosis and independent of lower lipid levels. Proinflammatory cytokines are significantly elevated in KC-Tie2 mouse sera, including levels of MCP-1, IL-12p70, TNFα, IL-17A and VEGF (a; mean ± SEM; n=5–11 per group) and S100A8/A9 expression is increased in skin and serum of KC-Tie2 animals (b). KC-Tie2 animals have significantly less total cholesterol, triglycerides and HDL compared to control mice (c; mean ± SEM; n=8 per group; p values indicated for each lipid in table). 4-colour flow cytometry reveals significant increases in splenic proatherogenic monocytes (CD90loB220loCD49bloNK1.1loLy6GloCD11cloIAbloF4/80loCD11bhiLy-6Chi). Representative flow cytometry and quantification of CD11b+F4/80loLy-6Chi cells (d; mean ± SEM; n =4 spleens per group).* P <0.05 vs. control animals.
Total cholesterol, triglyceride, and LDL cholesterol levels were lower in KC-Tie2 compared to control mice, although not all reached statistical significance. Reduced HDL levels were observed in KC-Tie2mice (Figure 3c).Specific monocyte sub-populations (i.e., Ly-6Chi) have been implicated in monocyte/macrophage vessel wall infiltration and atherosclerotic lesion formation. Therefore, we evaluated splenic and circulating CD11b+Ly-6Chi monocytes in KC-Tie2mice at 6 months of age prior to aortic root inflammation. Splenic CD11b+Ly-6Chi monocytes levels were increased by 42% (P=0.009) in KC-Tie2 compared to control mice (Figure 3d). Similar results were observed in circulating blood (Supplemental Figure 2).
Inflammation and thrombosis
Given the bi-directional link between inflammation and thrombosis, we assessed arterial thrombosis in KC-Tie2 compared to control mice using a photochemical (Rose Bengal-green light laser) carotid artery injury model, which produces thrombosis due to local free radical release and oxidative endothelial cell injury (Falati ; Furie and Furie, 2005; Watson ). The time to occlusive thrombus formation was shortened significantly in KC-Tie2 compared to control mice (n=9–10; 19 ± 3 vs. 53 ± 8 min, P=0.002) (Figure 4).
Figure 4
KC-Tie2 mice are pro-thrombotic. KC-Tie2 and control mice underwent experimental thrombosis; carotid artery blood flow was monitored continuously with a vascular flow probe, time to occlusion, defined as cessation of blood flow for 20 min, was recorded (a). Mean time (± SEM) to occlusive thrombus formation in control mice was 53 ± 8 minutes (n=10), and was shortened significantly in KC-Tie2 mice (19 ± 3 minutes; n=9; P=0.002). H&E stained carotid arteries from control and KC-Tie2 mice following Rose Bengal laser treatment. Note the fibrin-platelet rich thrombi with some red blood cells in the lumen of carotid arteries of KC-Tie2 and not control mice (b). *P<0.05 vs control animals. Scale bar = 100 μm.
Skin disease remission
To examine whether aggressive targeting of skin inflammation would reverse the presence of aortic root vascular lesions, 7 month old mice with severe skin disease were fed doxycycline-supplemented food to repress gene expression and reverse skin disease (Silver ; Wolfram ). At 12 months of age both skin inflammation (data not shown) and aortic root lesions were eliminated in KC-Tie2mice (0%; n=9; Figure 5a–f).
Figure 5
Repressing skin inflammation improves aortic root lesions and thrombosis clotting times. Seven month old KC-Tie2 mice (n=9) and control littermates (n=9) were treated with doxycycline to repress transgene expression and reverse skin inflammation. Aortic roots from representative 1 year old control (a, c, e) and KC-Tie2 (b, d, f) animals stained with H&E (a–b), Trichrome (c–d) and elastin (e–f). No aortic root lesions were observed in any control or KC-Tie2 doxycycline treated mice. (g) KC-Tie2 and control mice treated with doxycycline for 6 weeks underwent experimental thrombosis; mean time (± SEM) to occlusive thrombus formation was not significantly different between control mice treated with doxycycline (31 ± 8 minutes; n=10) and KC-Tie2 mice treated with doxycycline (36 ± 9 minutes; n=10; P=0.69). Scale bar = 100 μm.
To assess the effect of skin disease remission on occlusive thrombosis formation, KC-Tie2 and control animals were fed doxycycline-supplemented food for 6 weeks and then underwent photochemical carotid artery injury to produce thrombosis. Doxycycline treatment returned KC-Tie2thrombosis clotting times to control mouse levels (n=10; 31 ± 8 controls + doxycycline vs 36 ± 9 KC-Tie2 + doxycycline; P=0.69; Figure 5g). Control animals treated with doxycycline had slightly shorter clotting times than untreated control mice, however this difference was not significant (P=0.07).
DISCUSSION
In this study, we have identified that sustained skin inflammation itself is sufficient to promote vascular inflammation and thrombosis. This conclusion is supported by the following data: 1) KC-Tie2mice develop aortic root inflammatory lesions 2) Collagen content is decreased and elastin fragmentation is increased in the aortic root of KC-Tie2mice; 3) Pro-inflammatory cytokines and chemokines are increased in the skin and peripheral blood of KC-Tie2mice that precede the development of aortic root inflammatory lesions; 4) Inflammatory CD11b+ Ly-6Chi monocytes are elevated in KC-Tie2 animals prior to lesion development; 5) Thrombotic occlusion time after photochemical carotid injury is shortened in KC-Tie2mice; and 6) Aortic root inflammatory lesions and thrombosis clotting times significantly improve in KC-Tie2mice following skin disease repression.Psoriasispatients have an increased risk for developing CVD, including myocardial infarction and stroke. However the high prevalence of standard CVD risk factors in patients with psoriasis required statistical adjustments for the confounding effects of these variables in psoriasis epidemiological studies (Gelfand ; Gelfand ; Mehta ; Mehta ). Thus, the question of whether inflammatory hyperplastic disease confined to the skin has the capacity to directly cause vascular inflammation and thrombosis was, heretofore, unknown. It was highly beneficial to employ a murine model of psoriasis that recapitulates many aspects of the human disease (Johnston ; Ostrowski ; Swindell ; Ward ; Wolfram ), including the characteristic histologic, immunologic, and pro-inflammatory cytokine profiles as well as disease attenuation/clearance in response to clinically efficacious therapeutics, but without standard CVD risk factors (i.e., hyperlipidemia, hypertension, diabetes, obesity) to elucidate the effect of the disease itself. Using this model, our findings provide direct evidence linking skin inflammation with the development of vascular inflammation as well as an increased propensity for arterial thrombosis after endothelial redox-mediated injury.Chronic inflammation and pro-inflammatory cytokines play significant roles in the pathogenesis of both psoriasis and vascular disease. Evidence suggests that psoriasis and CVD share common pathogenic features (Alexandroff ; Spah, 2008), including immunological processes, inflammatory cytokine profiles, and the presence of local and systemic inflammatory markers (Alexandroff ; Boehncke ; Federman ; Gisondi and Girolomoni, 2009; Hansson, 2005; Libby, 2002; Lowes ; Ross, 1999; Spah, 2008). Activation of these inflammatory cells (dendritic cells, macrophages and T cells) together with the release of pro-inflammatory cytokines (e.g., TNF-α, IFN-γ, IL-12) contribute to the development of psoriatic lesions (Lowes ) and play a major role in the development and vulnerability of atherosclerotic plaque (Hansson, 2005; Libby, 2002; Libby and Simon, 2001; Ross, 1999). The idea that similar mechanisms underlie the development of both psoriasis and CVD is supported by findings of others (Shepherd ) such that sustained IL-1 signaling, accomplished via genomic deletion of the IL-1RA, resulted in three types of strain-dependent inflammatory changes, including a psoriasiform dermatitis in ear skin, arthritis-like inflammation in the joints, and large vessel arterial inflammation. However, this experimental approach resulted in increased IL-1 signaling throughout the body. The KC-Tie2mouse has confined gene expression of the membrane-bound Tie2 receptor to keratinocytes, thus our findings provide experimental evidence that keratinocyte signaling and cell-cell interactions within the cutaneous environment can initiate inflammation capable of causing vascular inflammatory foci formation in distant vessels, perhaps as a result of changes in both circulating proinflammatory cytokines and leukocytes (CD11b+ Ly-6Chi monocytes). KC-Tie2mice have increases in pro-inflammatory cytokines and chemokines and increases in splenic and circulating pro-inflammatory CD11b+Ly-6Chi monocytes that precede and are associated with the development of vascular inflammation and disease and occur independent of changes in lipids. The clinical relevance of our observations in KC-Tie2mice is supported by highly sensitive, metabolic imaging (i.e., [18F]-fluorodeoxyglucose positron emission tomography-computed tomography, FDG-PET/CT) in psoriasispatients showing concomitant aortic inflammation. Coupled with our thrombosis observations, this suggests that elevated levels of inflammation could potentially be used to predict poor outcomes and adverse cardiovascular events in patients with psoriasis. Taken together, these findings provide insight into skin-specific contributions underlying prior epidemiological reports that psoriasispatients are at increased risk for MI, stroke, venous thromboembolism and cardiovascular mortality (Ahlehoff ; Ahlehoff ; Gelfand ; Gelfand ; Mehta ; Mehta ; Prodanovich ).There is increasing evidence for an important link between inflammation and thrombosis. Leukocyte-platelet interactions induce bi-directional signals that amplify pro-inflammatory and pro-thrombotic cellular responses (Libby and Simon, 2001). Activated platelets and platelet-released mediators (e.g., PDGF and PAF) activate leukocytes, thereby enhancing their responses such as chemotaxis, ROS generation, phagocytosis, and pro-coagulant activity (Bazzoni ; Kuijper ; Lindemann ; Nagata ). Conversely, activated leukocytes induce platelet activation as evidenced by increased platelet P-selectin and activated glycoprotein IIb/IIIa expression (Li ). Psoriasispatients have elevated P-selectin and levels correlate with disease severity (Garbaraviciene ). The most compelling observation of this study relates to the finding that occlusive thrombus formation was shortened significantly in KC-Tie2 compared to control mice and supports recent epidemiological reports demonstrating psoriasispatients had higher incident rates of venous thromboembolism (Ahlehoff ). Acute myocardial infarction typically results from atherosclerotic plaque disruption or superficial endothelial cell erosion and thrombosis that cause coronary arterial occlusion (Davies and Thomas, 1985; Farb ). Yet, molecular events that precede acute myocardial infarction in patients with psoriasis remain uncertain. This mouse model provides valuable clues addressing this gap area in at-risk psoriasispatients. For example, both S100A8/A9 (Figure 3B) and MPO (data not shown), which are elevated in the skin and peripheral blood of KC-Tie2mice and psoriasispatients (Benoit ), have been implicated in acute coronary syndromes, including unstable angina and myocardial infarction (Baldus ; Healy ; Morrow ).Interestingly, most of the literature examining psoriasis and CVD report increases in either cardiovascular risk factors (diabetes, hypertension, hyperlipidemia)(Gelfand ; Mehta ; Prodanovich ), changes in CVD surrogate markers (MPO, adiponectin, S100A8/A9) (Benoit ; Kaur ; Takahashi ); or indirect measures of cardiovascular disease via endothelial function, carotid artery intimal-medial thickness (IMT)(Balci ) and stiffness measurements(Gisondi ). KC-Tie2 animals have elevated systemic inflammation independent of obesity, hyperglycemia and hyperlipidemia, demonstrating that skin inflammation alone can elicit systemic levels of inflammation critical for inflammatory lesion formation in the aortic root and promotion of thrombosis. Our observation of localized inflammation in the aortic root is consistent with the anatomical localization of aortic inflammation previously observed in psoriasispatients (Mehta ); and this foci of inflammation appears to be specific rather than representative of an overall generalized vascular inflammatory effect affecting all vessels of the body. Moreover, the location of vascular inflammatory lesions also correlates highly with sites that develop atherosclerosis in humans. Whether atherosclerosis is in fact elicited by psoriasis, remains unclear. We can not rule out that with time, these mice would develop atherosclerosis; however on a non-atherosusceptible genetic background strain, and with the short lifespan of a mouse, these experiments are not likely to yield insightful data addressing this issue. Rather, the usefulness of the murine model lends itself to modeling experiments whereby variables known to be increased in psoriasispatient's (i.e. dietary choices, V-LDL levels, ApoB, diabetic state, hypertension) could be manipulated in KC-Tie2 animals and the synergistic or additive effects of vascular inflammation coupled with the experimental manipulation on atherosclerotic plaque development and thrombosis could be examined.Our observations of aortic root vascular lesion resolution and improved thrombosis outcomes following skin-specific transgene repression provide further evidence demonstrating cutaneous inflammation promotes vascular inflammation and thrombosis and suggest that aggressive treatment of skin inflammation may attenuate pro-inflammatory and pro-thrombotic pathways that produce CVD in psoriasispatients. Although not skin-specific, recent prospective reports document significant improvement in endothelial vasodilator function (Boehncke ) and CVD biomarker levels (Boehncke ) in psoriasispatients following 24 weeks of systemic therapeutic treatment.Evidence linking chronic inflammation to the development of vascular inflammation is not limited to psoriasis. For example, periodontal disease is an important independent causal risk factor for atherosclerotic disease, including coronary heart disease and ischemic stroke (DeStefano ; Humphrey ). Importantly, periodontal therapy has been shown to alter gene expression of peripheral blood monocytes, suggesting that local therapies could have a systemic anti-inflammatory effect (Papapanou ). Similar to periodontal disease, rheumatoid arthritis is associated with increased carotid artery intimal:medial thickening as well as increased cardiovascular events independent of traditional cardiac risk factors. Prospective clinical trials are examining the effect of disease modifying therapies, such as anti-TNFα, on cardiovascular complications of rheumatoid arthritis.The results of our study provide strong evidence of remote, extravascular tissue inflammation promoting induction of CVD and suggest that suppression of skin inflammation is a viable approach worthy of investigation to favorably impact CVD complications of psoriasis.
METHODS
Animals
The KC-specific (K5-tTA) driver line and the TetosTek/Tie2 responder lines have been described previously (Diamond ; Jones ). Matings were performed between the K5tTA line and the TetosTek/Tie2 line and offspring were genotyped by polymerase chain reaction (PCR) using DNA extracted from ear biopsies as previously described (Wolfram ). We have previously demonstrated that animals inheriting a single copy of K5tTA and Tetos Tie2 (KC-Tie2 bi-transgenic mice) have ~50-fold increase in Tie2 mRNA and spontaneously develop a psoriasisform skin phenotype (Wolfram ). Male and female KC-Tie2 animals were used in the current studies and littermates inheriting one or no transgenes served as experimental controls. Transgene repression was completed as previously described (Silver ; Wolfram ).All animal protocols were approved by the Case Western Reserve University institutional animal care and use committee (IACUC) and conformed to the American Association for Accreditation of Laboratory Animal Care guidelines.
Protein analysis
See Online Supplement.
Flow cytometry
4-color flow cytometry was used to stain neutrophils, monocytes, and macrophages. Cells were incubated with a cocktail of mAbs against T cells (CD90-PE, 53–2.1), B cells (B220-PE, RA3-6B2), NK cells (CD49b-PE, DX5 and NK1.1-PE, PK136), neutrophils (Ly-6G–PE, 1A8), myeloid cells (CD11b-APC, M1/70) and monocyte subsets (Ly-6C–FITC, AL-21), as described previously (Shi ; Swirski ). F4/80 (BM8)-biotin-strep-PerCP, I-Ab (AF6-120.1)-biotin-strep-PerCP and CD11c (HL3)-biotin-strep-PerCP mAbs (BD Biosciences) also served to determine macrophage and dendritic cell differentiation (see also Online Supplement).
Histology and lesion analysis
Mice were perfused transcardially as previously described (Croce ) prior to dissection of the heart and aorta. For analysis of the aortic root, the bottom half of the heart was cut off in a plane parallel to the left and right atria. The top half of heart was embedded in paraffin after dehydration in ethanol and xylene. Serial 5μm heart sections were obtained and stained with Hematoxylin and Eosin (Sigma). Trichrome staining (Sigma) was performed to visualize collagen. Elastic laminae were visualized by staining the sections with Verhoeff–van Gieson (Sigma) as recommended by the manufacturer. Immune cell staining was completed as described in the Online Supplement.To quantitate the size of aortic root lesions, vessel wall area (including lesional area, if present) was measured using a computer-assisted image analysis program (Zeiss Axiovision software, Rel 4.5).
Photochemical carotid artery thrombosis
Ten week-old male and female KC-Tie2transgenic and littermate controls mice were anesthetized by intraperitoneal injection with sodium pentobarbital (62.5 mg/kg) and placed in the supine position on a dissecting microscope. Animals at this time point have established skin disease with abundant inflammatory cell infiltrate (Ostrowski ; Ward ; Wolfram ). Animals had a midline surgical incision made to expose the right common carotid artery and a Doppler flow probe (MC 0.5PSL Nanoprobe, Model 0.5 VB, Transonic Systems, Ithaca, NY) was placed under the exposed artery. The probe was connected to a flow meter (Transonic Systems Model TS420). Flow data was interpreted with a computerized data acquisition program (Windaq, DATAQ Instruments, Akron, OH). Rose Bengal at a concentration of 10 mg/mL in phosphate-buffered saline was then injected into the tail vein to administer a dose of 50 mg/kg. Following Rose Bengal injection, the mid portion of the common carotid artery was illuminated with a 1.5-mW green light laser source (540 nm; Melles Griot, Carlsbad, CA) 5 cm from the artery. Blood flow was monitored continuously from the onset of injury. The time to occlusion, determined only after the vessel remained closed with a cessation of blood flow for 20 min, was recorded.
Statistical analysis
All data are represented as mean ± standard error of the mean (SEM). Between group comparisons were analyzed using either a Student's T test or a Mann Whitney U test and statistical significance was defined as P<0.05.
Authors: Andrew Johnston; Xianying Xing; Andrew M Guzman; MaryBeth Riblett; Candace M Loyd; Nicole L Ward; Christian Wohn; Errol P Prens; Frank Wang; Lisa E Maier; Sewon Kang; John J Voorhees; James T Elder; Johann E Gudjonsson Journal: J Immunol Date: 2011-01-17 Impact factor: 5.422
Authors: Joel M Gelfand; Erica D Dommasch; Daniel B Shin; Rahat S Azfar; Shanu K Kurd; Xingmei Wang; Andrea B Troxel Journal: J Invest Dermatol Date: 2009-05-21 Impact factor: 8.551
Authors: Nehal N Mehta; Rahat S Azfar; Daniel B Shin; Andrea L Neimann; Andrea B Troxel; Joel M Gelfand Journal: Eur Heart J Date: 2009-12-27 Impact factor: 29.983
Authors: William R Swindell; Andrew Johnston; Steve Carbajal; Gangwen Han; Christian Wohn; Jun Lu; Xianying Xing; Rajan P Nair; John J Voorhees; James T Elder; Xiao-Jing Wang; Shigetoshi Sano; Errol P Prens; John DiGiovanni; Mark R Pittelkow; Nicole L Ward; Johann E Gudjonsson Journal: PLoS One Date: 2011-04-04 Impact factor: 3.240
Authors: Seemal R Desai; Ilona J Frieden; Joel M Gelfand; Whitney High; Arthur Kavanaugh; Ashfaq A Marghoob; David M Ozog; Ted Rosen; Linda Stein Gold; Bruce Strober; Neil Swanson; George Martin Journal: J Clin Aesthet Dermatol Date: 2015-09
Authors: Neal Bhatia; Andrew Blauvelt; Marc Brown; Whitney High; Craig T Leonardi; Ted Rosen; Linda Stein Gold; Eggert Stockfleth; Bruce Strober; Neil A Swanson; George Martin Journal: J Clin Aesthet Dermatol Date: 2014-07
Authors: George Martin; Bruce E Strober; Craig L Leonardi; Joel M Gelfand; Andrew Blauvelt; Arthur Kavanaugh; Linda Stein Gold; Brian Berman; Ted Rosen; Eggert Stockfleth Journal: J Clin Aesthet Dermatol Date: 2016-09-01
Authors: Julia Shlyankevich; Nehal N Mehta; James G Krueger; Bruce Strober; Johann E Gudjonsson; Abrar A Qureshi; Paul W Tebbey; Alexandra Boer Kimball Journal: Am J Med Date: 2014-08-19 Impact factor: 4.965
Authors: Yunmei Wang; Jackelyn B Golden; Yi Fritz; Xiufen Zhang; Doina Diaconu; Maya I Camhi; Huiyun Gao; Sean M Dawes; Xianying Xing; Santhi K Ganesh; Johann E Gudjonsson; Daniel I Simon; Thomas S McCormick; Nicole L Ward Journal: JCI Insight Date: 2016-12-08
Authors: Jackelyn B Golden; Sarah G Groft; Michael V Squeri; Sara M Debanne; Nicole L Ward; Thomas S McCormick; Kevin D Cooper Journal: J Immunol Date: 2015-07-29 Impact factor: 5.422